Skip to main content
Top
Published in: Clinical Rheumatology 4/2017

01-04-2017 | Original Article

Pachymeningitis in granulomatosis with polyangiitis: case series with earlier onset in younger patients and literature review

Authors: Violeta Higuera-Ortiz, Abraham Reynoso, Natllely Ruiz, Rosa Delia Delgado-Hernández, Gilberto Gómez-Garza, Luis Felipe Flores-Suárez

Published in: Clinical Rheumatology | Issue 4/2017

Login to get access

Abstract

The objective of this study is to describe the characteristics of patients with pachymeningitis (PM) in granulomatosis with polyangiitis (GPA) from Latin America, including three young patients. This is a retrospective case series. Patients were classified according to the ACR criteria, the 2012 Chapel Hill Consensus Conference Nomenclature and the EMA algorithm. Demographic, clinical, serological, and neuroimaging characteristics are described. Thirteen patients (nine females, four males) were identified. Mean age ± SD of PM diagnosis was 35.5 ± 20.4 years (median 48, range 8–71 years). Mean time ± SD between GPA first symptom and PM diagnosis was 59.8 ± 70.1 months (median 48, range 2–252 months). An important difference between children and adults was the median time elapsed between first GPA symptoms and PM diagnosis (range 2–4 months vs 5–252 months, respectively). Chronic headache was present in all, followed by intracranial hypertension (n = 5), single cranial nerve palsy and orbital mass (n = 4), seizures (n = 3), cavernous sinus syndrome and multiple cranial nerve palsies (n = 2), and meningism and cerebellar syndrome (n = 1 each). At time of PM diagnosis, mean BVAS/WG (Birmingham Vasculitis Activity Score for Wegener’s granulomatosis) was 4 ± 2.4 and mean VDI of 2 ± 1.6, mostly due to ENT damage. Gadolinium-enhanced brain MRI showed dural thickening in 12 patients and leptomeningeal enhancement in one. All received a combination of glucocorticoids plus immunosuppressants, rituximab being used favourably in one refractory case. Improvement was observed in 12 patients. Chronic headache should lead to suspect PM. PM predominates in localised GPA. Children may present it earlier in the disease course than adults. Treatment is non-standardised and remains difficult.
Literature
1.
go back to reference Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1–11CrossRefPubMed Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1–11CrossRefPubMed
2.
go back to reference Holle JU, Gross WL (2011) Neurological involvement in Wegener’s granulomatosis. Curr Opin Rheumatol 23:7–11CrossRefPubMed Holle JU, Gross WL (2011) Neurological involvement in Wegener’s granulomatosis. Curr Opin Rheumatol 23:7–11CrossRefPubMed
3.
go back to reference Baaj A, Vale FL, Carter JD, Rojiani AM (2009) Granulomatosis with CNS involvement: a neuroimaging clinicopathological correlation. J Neuroimaging 19:194–197CrossRefPubMed Baaj A, Vale FL, Carter JD, Rojiani AM (2009) Granulomatosis with CNS involvement: a neuroimaging clinicopathological correlation. J Neuroimaging 19:194–197CrossRefPubMed
4.
go back to reference Zhang W, Zhou G, Shi Q, Zhang X, Zeng XF, Zhang FC (2009) Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides. Clin Exp Rheumatol 27:S65–S69PubMed Zhang W, Zhou G, Shi Q, Zhang X, Zeng XF, Zhang FC (2009) Clinical analysis of nervous system involvement in ANCA-associated systemic vasculitides. Clin Exp Rheumatol 27:S65–S69PubMed
5.
go back to reference de Groot K, Schmidt DK, Arlt AC, Gross WL, Reinhold-Keller E (2001) Standardized neurological evaluations of 128 patients with Wegener granulomatosis. Arch Neurol 58:1215–1221CrossRefPubMed de Groot K, Schmidt DK, Arlt AC, Gross WL, Reinhold-Keller E (2001) Standardized neurological evaluations of 128 patients with Wegener granulomatosis. Arch Neurol 58:1215–1221CrossRefPubMed
6.
go back to reference Di Comite G, Bozzolo EP, Praderio L, Tresoldi M, Sabbadini MG (2006) Meningeal involvement in Wegener’s granulomatosis is associated with localized disease. Clin Exp Rheumatol 24:S60–S64PubMed Di Comite G, Bozzolo EP, Praderio L, Tresoldi M, Sabbadini MG (2006) Meningeal involvement in Wegener’s granulomatosis is associated with localized disease. Clin Exp Rheumatol 24:S60–S64PubMed
7.
go back to reference Nowack R, Wachtler P, Kunz J, Rasmussen N (2009) Cranial nerve palsy in Wegener’s granulomatosis—lessons from clinical cases. J Neurol 256:299–304CrossRefPubMed Nowack R, Wachtler P, Kunz J, Rasmussen N (2009) Cranial nerve palsy in Wegener’s granulomatosis—lessons from clinical cases. J Neurol 256:299–304CrossRefPubMed
8.
go back to reference Reinhold-Keller E, de Groot K, Holl-Urich K, Arlt AC, Heller M, Feller AC, Gross WL (2001) Severe CNS manifestations as the clinical hallmark in generalized Wegener’s granulomatosis consistently negative for antineutrophil cytoplasmic antibodies (ANCA). A report of 3 cases and a review of the literature. Clin Exp Rheumatol 19:541–549PubMed Reinhold-Keller E, de Groot K, Holl-Urich K, Arlt AC, Heller M, Feller AC, Gross WL (2001) Severe CNS manifestations as the clinical hallmark in generalized Wegener’s granulomatosis consistently negative for antineutrophil cytoplasmic antibodies (ANCA). A report of 3 cases and a review of the literature. Clin Exp Rheumatol 19:541–549PubMed
9.
go back to reference Bloch DA, Michel BA, Hunter GG et al (1990) The American Collegue of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods. Arthritis Rheum 33:1068–1073CrossRefPubMed Bloch DA, Michel BA, Hunter GG et al (1990) The American Collegue of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods. Arthritis Rheum 33:1068–1073CrossRefPubMed
10.
go back to reference Watts R, Lane S, Hanslik T et al (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222–227CrossRefPubMed Watts R, Lane S, Hanslik T et al (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222–227CrossRefPubMed
11.
go back to reference Stone JH, Hoffman GS, Merkel PA et al (2001) A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis activity score. International network for the study of the systemic vasculitides (INSSYS). Arthritis Rheum 44:912–920CrossRefPubMed Stone JH, Hoffman GS, Merkel PA et al (2001) A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis activity score. International network for the study of the systemic vasculitides (INSSYS). Arthritis Rheum 44:912–920CrossRefPubMed
12.
go back to reference Exley AR, Bacon PA, Luqmani RA et al (1997) Development and initial validation of the vasculitis damage index of the standardized clinical assessement of damage in the systemic vasculitides. Arthritis Rheum 40:371–380CrossRefPubMed Exley AR, Bacon PA, Luqmani RA et al (1997) Development and initial validation of the vasculitis damage index of the standardized clinical assessement of damage in the systemic vasculitides. Arthritis Rheum 40:371–380CrossRefPubMed
13.
go back to reference van Swieten JC, Koudstaal PJ, Mc V, Schouten HJ, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604–607CrossRefPubMed van Swieten JC, Koudstaal PJ, Mc V, Schouten HJ, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604–607CrossRefPubMed
15.
go back to reference Murphy JM, Gomez-Anson B, Gillard JH, Antoun NM, Cross J, Elliot JD, Lockwood M (1999) Wegener granulomatosis: MR imaging findings in brain and meninges. Radiology 213:794–799CrossRefPubMed Murphy JM, Gomez-Anson B, Gillard JH, Antoun NM, Cross J, Elliot JD, Lockwood M (1999) Wegener granulomatosis: MR imaging findings in brain and meninges. Radiology 213:794–799CrossRefPubMed
16.
go back to reference Holle JU, Voigt C, Both M et al (2013) Orbital masses in granulomatosis with polyangiitis are associated with refractory course and a high burden of local damage. Rheumatology 52:875–882CrossRefPubMed Holle JU, Voigt C, Both M et al (2013) Orbital masses in granulomatosis with polyangiitis are associated with refractory course and a high burden of local damage. Rheumatology 52:875–882CrossRefPubMed
17.
go back to reference Yokoseki A, Saji E, Arakawa M et al (2014) Hypertrophic pachymeningitis: significance of myeloperoxidase anti-neutrophil cytoplasmic antibody. Brain 137:520–536CrossRefPubMed Yokoseki A, Saji E, Arakawa M et al (2014) Hypertrophic pachymeningitis: significance of myeloperoxidase anti-neutrophil cytoplasmic antibody. Brain 137:520–536CrossRefPubMed
18.
go back to reference De Luna G, Terrier B, Kaminsky P et al (2015) Central nervous system involvement of granulomatosis with polyangiitis: clinical-radiological presentation distinguishes different outcomes. Rheumatology 54:424–432CrossRefPubMed De Luna G, Terrier B, Kaminsky P et al (2015) Central nervous system involvement of granulomatosis with polyangiitis: clinical-radiological presentation distinguishes different outcomes. Rheumatology 54:424–432CrossRefPubMed
19.
go back to reference Osborn AG, Blaser SI, Salzman KL et al (2004) Hypertrophic pachymeningtis. In: Osborn AG (ed) Diagnostic imaging: Brain, 1st edn. Amirsys, Salt Lake City, Utah, SII pp 30–33 Osborn AG, Blaser SI, Salzman KL et al (2004) Hypertrophic pachymeningtis. In: Osborn AG (ed) Diagnostic imaging: Brain, 1st edn. Amirsys, Salt Lake City, Utah, SII pp 30–33
20.
go back to reference Belostotsky VM, Shah V, Dillon MJ (2002) Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr Nephrol 17:754–761CrossRefPubMed Belostotsky VM, Shah V, Dillon MJ (2002) Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr Nephrol 17:754–761CrossRefPubMed
21.
go back to reference Akikusa JD, Schneider R, Harvey EA, Hebert D, Thorner PS, Laxer RM, Silverman ED (2007) Clinical features and outcome of pediatric Wegener’s granulomatosis. Arthritis Rheum 57:837–844CrossRefPubMed Akikusa JD, Schneider R, Harvey EA, Hebert D, Thorner PS, Laxer RM, Silverman ED (2007) Clinical features and outcome of pediatric Wegener’s granulomatosis. Arthritis Rheum 57:837–844CrossRefPubMed
22.
go back to reference Decimo I, Fumagalli G, Berton V, Krampera M, Bifari S (2012) Meninges: from protective membrane to stem cell niche. Am J Stem Cell 1:92–105 Decimo I, Fumagalli G, Berton V, Krampera M, Bifari S (2012) Meninges: from protective membrane to stem cell niche. Am J Stem Cell 1:92–105
Metadata
Title
Pachymeningitis in granulomatosis with polyangiitis: case series with earlier onset in younger patients and literature review
Authors
Violeta Higuera-Ortiz
Abraham Reynoso
Natllely Ruiz
Rosa Delia Delgado-Hernández
Gilberto Gómez-Garza
Luis Felipe Flores-Suárez
Publication date
01-04-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 4/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3520-6

Other articles of this Issue 4/2017

Clinical Rheumatology 4/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.